Kaleido Biosciences Inc
OTC:KLDO

Watchlist Manager
Kaleido Biosciences Inc Logo
Kaleido Biosciences Inc
OTC:KLDO
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 4.3k USD

Net Margin
Kaleido Biosciences Inc

-8 178.3%
Current
-6 473%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8 178.3%
=
Net Income
-90.3m
/
Revenue
1.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Kaleido Biosciences Inc
OTC:KLDO
4.3k USD
-8 178%
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
485.6B USD
27%
CH
Roche Holding AG
SIX:ROG
257.9B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP
16%
US
Merck & Co Inc
NYSE:MRK
265B USD
30%
CH
Novartis AG
SIX:NOVN
207.5B CHF
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.8B USD
16%
No Stocks Found

Kaleido Biosciences Inc
Glance View

Market Cap
4.3k USD
Industry
Pharmaceuticals

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.

KLDO Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8 178.3%
=
Net Income
-90.3m
/
Revenue
1.1m
What is the Net Margin of Kaleido Biosciences Inc?

Based on Kaleido Biosciences Inc's most recent financial statements, the company has Net Margin of -8 178.3%.

Back to Top